Giuseppe Michieli
Higher-Dose #Fluvoxamine and Time to Sustained #Recovery in #Outpatients With #COVID19, JAMA: https://jamanetwork.com/journals/jama/fullarticle/2812204?guestAccessKey=54d3e80d-56e9-4898-af7f-16af89f61123&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=111723&adv=000003719403
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19

This randomized study examines the effect of higher-dose fluvoxamine on time to sustained recovery from mild to moderate COVID-19 or progression to severe disease in nonhospitalized adults.

Nov 17, 2023 at 8:13pmWeb
Show threadGiuseppe MichieliNov 17, 2023
''Findings In this platform randomized clinical trial with 1175 US participants enrolled during the time that Omicron COVID-19 subvariants were circulating, there was no reportable difference in the time to sustained recovery between fluvoxamine and placebo groups (adjusted hazard ratio, 0.99 [95% credible interval, 0.89-1.09]; P for efficacy = .40). Median time to sustained recovery was 10 days (95% CI, 10-11) in both the intervention and placebo group.'